Abcam, ab263318, Human PTGFRN knockout HeLa cell lysate

Size: 1Kit
PTGFRN KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 4 bp deletion in exon2.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 4 bp deletion in exon2.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PTGFRN, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PTGFRN also known as Prostaglandin F2 receptor negative regulator is a membrane protein with a mass of approximately 94 kDa. This protein is expressed on various cell types including immune cells like monocytes and macrophages as well as in the heart and lung tissues. PTGFRN interacts with other membrane proteins to modify signalling pathways particularly those involving G-protein-coupled receptors.
Biological function summary
PTGFRN modulates prostaglandin-mediated signaling serving as a regulatory component that dampens the response to prostaglandin F2 alpha. It is part of a multi-protein complex which includes interactions with proteins like CD9 and integrins. These interactions influence cell adhesion and mobility making PTGFRN relevant in processes like inflammation and tissue repair.
Pathways
PTGFRN plays a significant role in the prostaglandin signaling cascade affecting signal transduction linked with inflammatory responses. It is closely associated with the PI3K/Akt pathway a critical pathway for cellular survival and proliferation. The interactions between PTGFRN and CD9 or integrins facilitate the integration of signals that modify cell growth and immune function.
PTGFRN has been implicated in heart failure and inflammatory lung diseases like chronic obstructive pulmonary disease (COPD). In heart failure PTGFRN can interact with integrins to influence cardiac remodeling and fibrosis. In COPD its regulatory function within the prostaglandin pathway affects inflammatory responses. Understanding these interactions provides insights into potential therapeutic targets for managing these conditions.